Engineered immune cells show promise against hard-to-treat leukemia
NCT ID NCT03984968
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for adults with a specific type of leukemia (Philadelphia chromosome-positive B-ALL). The treatment uses a patient's own immune cells that are modified in a lab to find and attack cancer cells. The goal is to see if this approach is safe and can help keep the cancer from coming back after initial treatment. About 40 people will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, ADULT B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China